In another study, though BRAF-mutant CRCs were more sensitive to Dabrafenib (BRAF inhibitor) and Trametinib (MEK inhibitor) combination therapy than to Dabrafenib (BRAF inhibitor) single agent therapy, the response seen was less impressive than what has been observed in melanoma [38]. The gene discussed is MAP2K7; the disease is melanoma.